ESMO Immuno-Oncology 2025 | Neoadjuvant pembrolizumab strategies in solid tumors
Hans Nijman, MD, University Medical Center, Groningen, Netherlands, discusses the follow-up trial of a previously published study, which is currently ongoing and investigating the use of nine courses of neoadjuvant pembrolizumab in solid tumors. Combining checkpoint inhibitors may have synergistic effects with other drugs to induce both IgG and IgA responses, eradicating tumors more efficiently. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so first of all, what we’re doing now is the follow-up trial of the one we published. And that’s an ongoing trial in which we gave nine courses of pembrolizumab neoadjuvantly. Last patient in will be hopefully next week so hopefully in a short period of time we can tell you all about what’s going on in that one so so that’s one thing two courses is great but to really eradicate the tumor you need more we think nine courses might do the job the other thing is what we observed and what I told you is that there is a shift...
Yeah, so first of all, what we’re doing now is the follow-up trial of the one we published. And that’s an ongoing trial in which we gave nine courses of pembrolizumab neoadjuvantly. Last patient in will be hopefully next week so hopefully in a short period of time we can tell you all about what’s going on in that one so so that’s one thing two courses is great but to really eradicate the tumor you need more we think nine courses might do the job the other thing is what we observed and what I told you is that there is a shift. Normally spoken, you have IgA and IgG in animal cancer to be shown and probably having a position. The moment you give neoadjuvant, you get skewing towards IgG. So a fair reason to think of might be, what can I do to make sure that you not only get IgG, but also IgA? So how can I combine my checkpoint inhibitor with another drug, making sure that I do not only have IgG, but also IgA, so that they can do and work together and try to do the job even more efficiently getting your tumor eradicated. So that’s just one thought, but many things to explore. And well, hopefully we have some nice discussions in London at ESMO and see what others think of it.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
